The antimitotic depsipeptide dolastatin 15 was radiolabeled with tritium in its amino-terminal dolavaline residue. Dolastatin 15, although potently cytotoxic, is a relatively weak inhibitor of tubulin assembly and does not inhibit the binding of any other ligand to tubulin. The only methodology found to demonstrate an interaction between the depsipeptide and tubulin was Hummel-Dreyer equilibrium chromatography on Sephadex G-50 superfine. The average apparent K d value obtained in these studies was about 30 lM, with no difference observed when column size or tubulin concentration was varied. This relatively high dissociation constant is consistent with the apparent weak interaction of dolastatin 15 with tubulin demonstrated indirectly in the assembly assay. We attempted to gain insight into the binding site for dolastatin 15 on tubulin by studying inhibitory effects of other drugs when the gel filtration column was equilibrated with both [ 3 H]dolastatin 15 and a second, nonradiolabeled drug. No inhibition was detected with either the colchicine site agent combretastatin A-4 or with an analog of the antimitotic marine peptide diazonamide A (both the analog and diazonamide A are potent inhibitors of tubulin assembly). Weak inhibition was observed with cemadotin, a structural analog of dolastatin 15, and with the depsipeptide cryptophycin 1. Moderate inhibition occurred with vinblastine and vincristine, and strong inhibition with maytansine, halichondrin B, and the peptides dolastatin 10 and phomopsin A. These observations suggest that the binding site(s) for peptide and depsipeptide antimitotic drugs may consist of a series of overlapping domains rather than a well-defined locus on the surface of b-tubulin.
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Tubulin, the subunit protein of microtubules, is the intracellular target of an increasing number of antimitotic peptides and depsipeptides. These compounds are all natural products containing unusual, frequently unique, amino acids, and they invariably inhibit microtubule assembly (recently reviewed [1] ). Most of these peptides are highly cytotoxic, inhibiting the growth of cultured cells with picomolar or low nanomolar IC 50 values, and, as is typical with drugs that target tubulin, treated cells arrest in the mitotic phase of the cell cycle. Most of these peptides and synthetic analogs inhibit the binding of vinca alkaloids to tubulin in a noncompetitive manner [2] [3] [4] [5] [6] .
A notable exception to this generalization has been the depsipeptide dolastatin 15, originally extracted from the sea hare Dolabella auricularia [7] , and its synthetic analog cemadotin [8] (structures in Fig. 1 ). Neither compound inhibited the binding of vinblastine to tubulin [8, 9] , and it was also reported that vinblastine did not inhibit the binding of radiolabeled cemadotin to tubulin [10] . Therefore, it seemed possible that dolastatin 15 and cemadotin might bind in a unique site on tubulin. To evaluate this idea, we synthesized radiolabeled dolastatin 15 and sought a method to study its interaction with tubulin, both in the presence and absence of potential competitors. Our primary goal was to gain new insights into the potential relationships between binding site(s) for different antimitotic peptides and between binding sites for the peptides and for other compounds that inhibit binding of vinca alkaloids to tubulin.
Despite many efforts to detect a tubulinAEdolastatin 15 interaction, we only succeeded when we employed the cumbersome Hummel-Dreyer chromatographic method [11] . Utilizing progressively smaller columns, we were able to adapt this technique to obtain qualitative information about relative inhibitory effects on the binding of dolastatin 15 by a number of vinca domain drugs. We were unable, however, to determine which compounds might be competitive or noncompetitive inhibitors of dolastatin 15 binding, because we did not have adequate amounts of either [ 3 H]dolastatin 15 or most of the potential inhibitors to perform the detailed studies at multiple concentrations required for such an evaluation.
Most of the vinca domain drugs that we examined inhibited dolastatin 15 binding in parallel with their inhibitory effects on dolastatin 10 binding and vinca alkaloid binding to tubulin. The major exception was cryptophycin 1. Although a strong inhibitor of dolastatin 10 and vinblastine binding [3] , this depsipeptide had minimal inhibitory effect on dolastatin 15 binding. This suggests to us that the vinca domain is most likely a relatively large binding pocket on the surface of b-tubulin that is able to accommodate different complex natural product ligands by diverse binding mechanisms, presumably involving different, possibly adjacent and/or overlapping, subsites.
Materials and methods

Materials
Bovine brain tubulin was purified as described previously [12] , including gel filtration chromatography on Sephadex G-50 (superfine) [13] . Nonradiolabeled dolastatin 15, dolastatin 10, and combretastatin A-4 were synthesized as described previously [14] [15] [16] . Cemadotin, maytansine, vinblastine, vincristine, and halichondrin B were generously provided by the Drug Synthesis and Chemistry Branch, National Cancer Institute. Cryptophycin 1 [17] was a generous gift from Merck, Sharp and Dohme Research Laboratories (Rahway, NJ, USA), and compound 1, an analog of diazonamide A, was synthesized as described elsewhere [18] . Phomopsin A was obtained from Calbiochem. , and 3 or 10 mg was applied to the 48 · 1.5-cm columns, 10 mg was applied to the 24 · 1.5-cm columns, and 5 mg was applied to the 30 · 0.7-cm columns.
Methods
The
Data were analyzed in all cases by assuming a simple tubulin-drug equilibrium:
and
The equilibrated column radiolabel was used as the concentration of unbound dolastatin 15, the radiolabel above this level in a protein-containing fraction was taken as the tubulinAEdolastatin 15 concentration, and the free tubulin concentration was obtained by subtraction (total tubulin concentration, from the protein assay, minus the tubulinAEdolastatin 15 concentration). Two apparent K d values were obtained in each experiment by using the two fractions containing the highest amounts of protein for these calculations. Results and discussion 
Binding of dolastatin 15 to tubulin is inhibited by its synthetic analog cemadotin but not by a colchicine site drug
We reasoned that if the column were equilibrated with both dolastatin 15 and another drug, an inhibitory effect would manifest itself as reduced radiolabel associated with the protein peak, resulting in an increase in the calculated apparent K d value for dolastatin 15. Alternatively, if no inhibition occurred, the apparent K d value should be unaltered.
This was tested with cemadotin, on the one hand, and with combretastatin A-4, a potent colchicine site drug [21] , on the other (Table 1) . With the highest feasible cemadotin concentration (determined by the amount of the drug we could obtain), 100 lM, there was > 50% reduction in the amount of [ 3 H]dolastatin 15 bound to tubulin, with a concomitant rise in the calculated apparent K d value to 85 lM ( Table 1 ). In contrast, two concentrations of combretastatin A-4, which is at least 10-fold more active than both dolastatin 15 and cemadotin as an inhibitor of tubulin assembly and a powerful competitive inhibitor of the binding of colchicine to tubulin [21] , did not alter the apparent K d value for the binding of [ 
Inhibition of dolastatin 15 binding by vinca domain drugs
As noted above, dolastatin 15 differs from most other antimitotic peptides and depsipeptides in not inhibiting vinca alkaloid binding to tubulin, nor does it inhibit dolastatin 10 binding to tubulin. Moreover, despite its potent cytotoxic properties, dolastatin 15 is about 5 to 20-fold less active as an inhibitor of tubulin assembly than dolastatin 10, cryptophycin 1, hemiasterlin, and phomopsin A, depending on precise reaction conditions. Thus, it is conceivable that dolastatin 15 binds with lower affinity in the same site as the other peptides. The apparent K d we obtained for dolastatin 15 is consistent with this possibility, being substantially higher than the apparent K d values of 26 nM and 0.1-0.45 lM obtained, respectively, for dolastatin 10 [25] and cryptophycin 52 [26] , which is a synthetic analog of cryptophycin 1 with activity equivalent to that of the natural product [27] .
Alternatively, it is possible that dolastatin 15 binds at an independent site on tubulin different from that where dolastatin 10, phomopsin A, cryptophycin 1, and hemiasterlin bind. Examination of this possibility became more important with the recent discovery that diazonamide A and its close analog compound 1, like dolastatin 15, do not significantly inhibit the binding of [ [22] and [ 3 H]dolastatin 10 to tubulin. An additional similarity between diazonamide A/compound 1 and dolastatin 15 is that these compounds do not interfere significantly with nucleotide exchange on b-tubulin. In contrast to dolastatin 15, however, diazonamide A and compound 1 are as potent as dolastatin 10 as inhibitors of tubulin assembly [24] .
Examination of various vinca domain drugs and compound 1 for inhibitory effects on the tubulinAEdolastatin 15 interaction might provide information about the binding site of the depsipeptide on the protein relative to the other compounds. The selection of agents was determined only by availability of sufficient compound to equilibrate and develop the Hummel-Dreyer columns. The results obtained are summarized quantitatively in Table 1 Table 2 for comparison with available data on drug inhibitory effects on the binding of vinca alkaloids and dolastatin 10 to tubulin.
While there appears to be a wide range of effects on the apparent K d values, a critical examination of the actual data used to generate the values shown in Table 1 revealed that values over about 500 lM should be considered equivalent and indicative of a strong inhibitory effect. Values > 500 lM were all observed when inhibition of dolastatin 15 binding was > 90%, with differences in the calculated apparent K d values therefore of limited reliability. As a specific example, the experimental data obtained from one of the columns, in which the effect of 50 lM maytansine was examined, are shown in Fig. 4 , with details summarized in the legend. The radiolabel associated with the two fractions containing the highest amounts of protein was only % 2% above the column equilibrium level, and the standard deviation of the radiolabel in the fractions used to establish the equilibrium level was % 1% of the average value. Combining these small increases in radiolabel with the protein concentrations in the two fractions yielded apparent K d values of % 1300 and % 800 lM. Thus, for purposes of this discussion, an increase in the apparent K d value to 50-100 lM will be considered weak inhibition, to 100-500 lM as moderate inhibition, and to > 500 lM as strong inhibition.
Every compound examined, with the exceptions of compound 1 and the colchicine site drug combretastatin A-4, inhibited binding of dolastatin 15 to tubulin (Table 1) . Weak inhibition was observed with saturating (nominally 50 lM) cryptophycin 1, moderate inhibition with vinblastine and vincristine, and strong inhibition with dolastatin 10, phomopsin A, maytansine, and halichondrin B. A complicating factor in interpretation of these inhibitory data is that dolastatin 10 [2,28], phomopsin A [2, 29] , cryptophycin 1 [3, 30, 31] , cemadotin [8] , and vinblastine and vincristine [32] , besides inhibiting microtubule assembly, all induce formation of complex, morphologically distinct, structurally aberrant oligomers and/or polymers of tubulin. It is possible that a binding site for dolastatin 15 could be inaccessible in these aberrant structures. However, while difficult to exclude, such a phenomenon has not yet been demonstrated as occurring between two classes of drug that inhibit microtubule assembly. In fact, it has often been observed that different drug classes tend to enhance each other's binding, an observation usually explained in terms of ligand stabilization of the overall conformation of tubulin.
When the inhibitory effects of the compounds examined with [ 3 H]dolastatin 15 are compared qualitatively with those previously observed with radiolabeled dolastatin 10 and radiolabeled vinca alkaloids (Table 2) , the results for the most part are reasonably parallel. They do not, however, seem to be related to whether competitive or noncompetitive inhibition patterns were observed. Thus, dolastatin 10/19aR-isodolastatin 10 and phomopsin A are strong inhibitors of the binding of all three ligands, while dolastatin 15/cemadotin and compound 1 are weak inhibitors or noninhibitory. Maytansine and halichondrin B were moderate inhibitors of dolastatin 10 binding and strongly inhibited vinca alkaloid binding and dolastatin 15 binding.
In cross-inhibition studies with the two vinca alkaloids, vincristine seemed to bind to tubulin more tightly than vinblastine, and these relative activities were reflected in greater inhibition by vincristine than vinblastine of dolastatin 10 binding. In the present studies, however, we found little difference in their inhibitory effects on dolastatin 15 binding. Our observation of moderate inhibition of dolastatin 15 binding by vinblastine contrasts with the failure of Jordan et al. [10] to observe inhibition by vinblastine of the binding of cemadotin to tubulin, using the centrifugal gel filtration methodology.
The most distinctive pattern was obtained with cryptophycin 1. Despite the depsipeptide's potent inhibition of In addition, the failure of compound 1, and presumably diazonamide A, to inhibit [ 3 H]dolastatin 15 binding re-emphasizes the unique properties of these new antimitotic peptides. Despite their potent inhibition of assembly, suggesting a relatively strong interaction with tubulin, these peptides seem unable to inhibit the binding of vinblastine, dolastatin 10, dolastatin 15, or colchicine to tubulin. This may indicate an exceptionally weak interaction with unpolymerized tubulin (the ab-tubulin heterodimer), presumably in the vinca domain, a truly unique binding site, or, perhaps, a specific affinity for microtubule ends and not for the heterodimer.
In conclusion, we have been able to demonstrate by Hummel-Dreyer chromatography that dolastatin 15 has a relatively low binding affinity (apparent K d of % 30 lM) for the ab-tubulin heterodimer and that the Hummel-Dreyer method may be modified to document inhibitory effects on ligand binding. Because of the large number of compounds that interfered with the tubulin-dolastatin 15 interaction, we were unable to definitively characterize the binding site for dolastatin 15 on tubulin. This binding site does appear to be within the Ôvinca domainÕ, even though both competitive and noncompetitive inhibitors of vinca alkaloid binding to tubulin had similar inhibitory effects on the binding of dolastatin 15 to tubulin. The most unexpected findings were the weak inhibition of dolastatin 15 binding by cryptophycin 1 and the complete failure of the diazonamide A analog compound 1 to inhibit dolastatin 15 binding. While our results here and in earlier studies [24] have provided no insight into the binding site for diazonamide A on tubulin, the cryptophycin 1 result suggests that our concept of a Ôpeptide siteÕ should be modified.
The peptide site was originally proposed to explain findings with dolastatin 10 and with chiral isomers and segments of dolastatin 10 [2] . The concept seemed to be validated when hemiasterlin, phomopsin A, and cryptophycin 1 were all found to be competitive inhibitors of the binding of [ We wish to note that, in principle, it should be possible to adapt the Hummel-Dreyer method to obtain more specific data about drug binding sites (e.g. whether binding is competitive or noncompetitive). This would require accumulation and analysis of data obtained at multiple drug concentrations, but we did not have adequate amounts of either [ Finally, the relatively low affinity of both dolastatin 15 and cemadotin for tubulin contrasts with their potent cytotoxicity. Although this apparent discrepancy could indicate that the tubulin-microtubule system is not the primary or only target for these drugs, this seems unlikely. Dolastatin 15 and cemadotin cause classic mitotic arrest with disappearance of intracellular microtubules [8, 9] , and cemadotin dramatically suppresses microtubule dynamics [10] . These are cellular effects always observed with drugs that are believed to exert their cytotoxicity through an inhibitory interaction with the microtubule system. One possible explanation for the potent cytotoxicity of dolastatin 15 and cemadotin is that these agents are metabolized intracellularly to a compound with increased affinity for tubulin, perhaps involving hydrolysis of the ester bond of dolastatin 15 or removal of the benzamide group in cemadotin. Pettit et al. [33] described the synthesis of a large series of dolastatin 15 analogs, all possessing the amino-terminal pentapeptide and different groups at the carboxy-side of the ester bond. None was as active as dolastatin 15 in a tubulin-based assay, but they all had antimitotic activity equivalent to that of dolastatin 15, leading to the proposal that a common intracellular metabolite might be responsible for the activity of the compounds. A similar proposal has been made to account for the activity of cemadotin [8] , but an active intracellular metabolite with enhanced affinity for tubulin has yet to be documented.
